Editas Medicine EDIT

HealthcareMarket cap $400M1 connection

Editas Medicine is one of the original CRISPR companies, developing gene editing therapies for rare diseases. Its EDIT-101 program for Leber congenital amaurosis (LCA10) was the first in-vivo CRISPR therapy dosed in a human. Despite challenges, Editas holds foundational CRISPR IP through its Broad Institute license.

Open Editas Medicine's Company Hub Simulate a merger Supply chain See it on the map

Partners 1

Strategic partnerships, joint products and alliances

CRISPR TherapeuticsHealthcare · $5BEditas and CRISPR Therapeutics competing CRISPR IP

Other Healthcare companies

Eli Lilly Johnson & Johnson AbbVie Novo Nordisk Merck UnitedHealth Thermo Fisher AstraZeneca Amgen Novartis

Embed this on your site

Show Editas Medicine's network in an article or report - it updates as our data does.

<iframe src="https://vexmap.com/embed.html?co=EDIT" width="600" height="420" style="border:0;border-radius:12px;max-width:100%" title="Editas Medicine on VexMap" loading="lazy"></iframe>

Preview

Relationships are compiled by VexMap from company filings, announcements and reporting, and last reviewed September 2026. Spotted something wrong? Tell us. Not investment advice.